Imperial College London
Portrait Picture

Professor Mark Gilchrist

Faculty of Medicine, Department of Infectious Disease

Professor of Practice
 
 
 
//

Contact

 

m.gilchrist

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Satta:2021:10.7861/clinmed.2020-1021,
author = {Satta, G and Youngstein, T and Lightstone, L and Gilchrist, M and COVID-19, treatment guidelines working group at Imperial College Healthcare NHS Trust},
doi = {10.7861/clinmed.2020-1021},
journal = {Clinical medicine (London, England)},
pages = {e287--e289},
title = {The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic},
url = {http://dx.doi.org/10.7861/clinmed.2020-1021},
volume = {21},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Coronavirus disease 2019 (COVID-19) was first identified in December 2019 in Wuhan, China. The first analyses of cases described high numbers of critically ill patients requiring intensive care admission with significant late inflammatory features. By the time the first cases of SARS-CoV-2 infection were diagnosed in the UK, a wide range of drugs were under consideration and it became clear that the input of clinicians covering all organ systems (in particular, infectious diseases, haematology, rheumatology, renal medicine and intensive care) and of expert specialist pharmacists was necessary at the local level. Thus, an expert multidisciplinary (MDT) group within our organisation was convened to offer a standardised approach and robust clinical governance for the treatment of COVID-19 patients admitted to our hospitals and rapidly develop standards of care as evidence evolved. This commentary explores the methods and mechanisms for creating an MDT COVID-19 treatment working group which are applicable to any hospital likely to admit and care for high numbers of COVID-19 patients and demonstrates how the structure and governance of the group allowed for rapid adoption of both dexamethasone and tocilizumab into standard of care as data became available.
AU  - Satta,G
AU  - Youngstein,T
AU  - Lightstone,L
AU  - Gilchrist,M
AU  - COVID-19,treatment guidelines working group at Imperial College Healthcare NHS Trust
DO  - 10.7861/clinmed.2020-1021
EP  - 289
PY  - 2021///
SN  - 1470-2118
SP  - 287
TI  - The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic
T2  - Clinical medicine (London, England)
UR  - http://dx.doi.org/10.7861/clinmed.2020-1021
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33782041
UR  - https://www.rcpjournals.org/content/clinmedicine/early/2021/03/27/clinmed.2020-1021
UR  - http://hdl.handle.net/10044/1/87438
VL  - 21
ER  -
Download